Kiniksa Pharmaceuticals International Plc.’s recent filing unveils that its CHAIRMAN & CEO Patel Sanj K unloaded Company’s shares for reported $3.49 million on Jul 23 ’24. In the deal valued at $25.65 per share,136,124 shares were sold. As a result of this transaction, Patel Sanj K now holds 63,012 shares worth roughly $1.62 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Ragosa Mark sold 24,248 shares, generating $601,108 in total proceeds. Upon selling the shares at $24.79, the CHIEF FINANCIAL OFFICER now owns 19,253 shares.
Before that, Paolini John F. sold 22,000 shares. Kiniksa Pharmaceuticals International Plc. shares valued at $578,966 were divested by the CHIEF MEDICAL OFFICER at a price of $26.32 per share. As a result of the transaction, Paolini John F. now holds 47,803 shares, worth roughly $1.23 million.
Wells Fargo initiated its Kiniksa Pharmaceuticals International Plc. [KNSA] rating to an Overweight in a research note published on May 03, 2024; the price target was $34. A number of analysts have revised their coverage, including BofA Securities’s analysts, who remained covering the stock and in late June has reiterated a ‘”a Buy”‘ rating for it. BofA/Merrill began covering KNSA with “Buy” recommendation on April 01, 2020. Barclays started covering the stock on March 11, 2019. It rated KNSA as “an Overweight”.
Price Performance Review of KNSA
On Tuesday, Kiniksa Pharmaceuticals International Plc. [NASDAQ:KNSA] saw its stock jump 1.70% to $25.72. Over the last five days, the stock has gained 5.93%. Kiniksa Pharmaceuticals International Plc. shares have risen nearly 46.64% since the year began. Nevertheless, the stocks have risen 50.41% over the past one year. While a 52-week high of $27.88 was reached on 07/23/24, a 52-week low of $14.12 was recorded on 04/19/24. SMA at 50 days reached $21.47, while 200 days put it at $19.16.
Levels Of Support And Resistance For KNSA Stock
The 24-hour chart illustrates a support level at 25.40, which if violated will result in even more drops to 25.07. On the upside, there is a resistance level at 25.91. A further resistance level may holdings at 26.09. The Relative Strength Index (RSI) on the 14-day chart is 64.10, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.00, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 42.09%. Stochastics%K at 49.19% indicates the stock is a holding.
How much short interest is there in Kiniksa Pharmaceuticals International Plc.?
A steep rise in short interest was recorded in Kiniksa Pharmaceuticals International Plc. stocks on
The most recent change occurred on December 12, 2018 when Wedbush resumed its ‘”an Outperform”‘ rating for the stock and retained the price target to $33.
